Forsteo Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

forsteo

eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. f'nisa wara l-menopawża, intwera tnaqqis sinifikanti fl-inċidenza ta 'ksur vertebrali u mhux vertebrali iżda mhux fratturi tal-ġenbejn. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Terrosa Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

terrosa

gedeon richter plc. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - terrosa hija indikata fl-adulti. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. f'nisa wara l-menopawża, intwera tnaqqis sinifikanti fl-inċidenza ta 'ksur vertebrali u mhux vertebrali iżda mhux fratturi tal-ġenbejn. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Livogiva Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

livogiva

theramex ireland limited - teriparatide - l-osteoporożi - homeostasi tal-kalċju - livogiva is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Enhertu Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplażmi tas-sider - aġenti antineoplastiċi - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Sondelbay Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

sondelbay

accord healthcare s.l.u. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - sondelbay is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Eladynos Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

eladynos

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - homeostasi tal-kalċju - trattament ta 'l-osteoporożi f'nisa wara l-menopawża b'riskju akbar ta' ksur.

Cholib Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

cholib

viatris healthcare limited - fenofibrate, simvastatin - dyslipidemias - aġenti li jimmodifikaw il-lipidi - cholib huwa indikat bħala terapija adjunctive tad-dieta u jeżerċita fir-riskju għoli kardjovaskulari pazjenti adulti ma dyslipidaemia imħallat li tnaqqas it-trigliċeridi u jżidu l-livelli hdl c meta livelli ldl c huma kkontrollati b'mod adegwat bl-doża korrispondenti ta ' l- simvastatin monotherapy.

Hepsera Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

hepsera

gilead sciences ireland uc - adefovir dipivoxil - epatite b, kronika - inibituri nucleoside u nucleotide reverse transcriptase - hepsera hija indikata għat-trattament ta 'epatite b kronika f'adulti b': mard tal-fwied kumpensat u b'evidenza ta ' replikazzjoni virali attiva, persistenti elevati fis-serum-alanine-aminotransferase (alt) livelli u evidenza istoloġika ta'infjammazzjoni tal-fwied attiva u fibrożi. il-bidu ta 'hepsera it-trattament għandu jiġi kkunsidrat biss meta l-użu ta' sustanza antivirali alternattiva bl-ogħla ġenetiċi barriera għall-reżistenza mhix disponibbli jew ikun xieraq (ara sezzjoni 5. 1);mard tal-fwied dekompensat flimkien mal-tieni aġent mingħajr kross-reżistenza għal hepsera.

Movymia Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

movymia

stada arzneimittel ag - teriparatide - l-osteoporożi - homeostasi tal-kalċju - movymia huwa indikat fl-adulti. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. f'nisa wara l-menopawża, intwera tnaqqis sinifikanti fl-inċidenza ta 'ksur vertebrali u mhux vertebrali iżda mhux fratturi tal-ġenbejn. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Zeffix Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

zeffix

glaxosmithkline (ireland) limited - lamivudine - epatite b, kronika - antivirali għal użu sistemiku - zeffix is indicated for the treatment of chronic hepatitis b in adults with: , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. il-bidu tal-kura b'lamivudine għandhom jiġu kkunsidrati biss meta l-użu ta ' sustanza antivirali alternattiva bl-ogħla ġenetiċi barriera ma tkunx disponibbli jew ikun xieraq;, mard tal-fwied dekompensat flimkien mal-tieni aġent mingħajr kross-reżistenza għal lamivudine.